{"id":560873,"date":"2026-07-01T18:00:00","date_gmt":"2026-07-01T16:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha\/"},"modified":"2026-07-10T18:00:31","modified_gmt":"2026-07-10T16:00:31","slug":"retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha\/","title":{"rendered":"Retatrutid y el programa TRIUMPH: el agonista triple en marcha"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>El tratamiento de la obesidad basado en las incretinas ha evolucionado r\u00e1pidamente en pocos a\u00f1os: desde los agonistas del receptor del GLP-1 (semaglutida), pasando por el agonista dual GIP\/GLP-1 tirzepatida, hasta llegar a un <em>agonista triple. <\/em>El retatrutido (LY3437943), como mol\u00e9cula \u00fanica, activa tres receptores simult\u00e1neamente: los del polip\u00e9ptido insulinotr\u00f3pico dependiente de la glucosa (GIP), el del p\u00e9ptido similar al glucag\u00f3n tipo 1 (GLP-1) y el del glucag\u00f3n. Esta ampliaci\u00f3n sigue una l\u00f3gica plausible: con cada mecanismo de acci\u00f3n adicional, la reducci\u00f3n media de peso aument\u00f3 en los estudios, desde el GLP-1 solo, pasando por el GLP-1 m\u00e1s el GIP, hasta la combinaci\u00f3n triple. El retatrutido es, hasta la fecha, el representante m\u00e1s avanzado de esta nueva clase y ha suscitado un gran inter\u00e9s en 2025\/2026 con los primeros resultados de fase III del programa TRIUMPH.<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fretatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>El tratamiento de la obesidad basado en las incretinas ha evolucionado r\u00e1pidamente en pocos a\u00f1os: desde los agonistas del receptor del GLP-1 (semaglutida), pasando por el agonista dual GIP\/GLP-1 tirzepatida,&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fretatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cardiometabolismo","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11352,11475,11478,11288,11354,11430],"tags":[95580,95578,17397,72483,95579],"powerkit_post_featured":[],"class_list":["post-560873","post","type-post","status-publish","format-standard","category-rx-es","category-cardiologia","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-medicina-interna-general","category-nutricion","category-prevencion-y-asistencia-sanitaria","tag-agonista-triple","tag-retatrutid","tag-semaglutida-es","tag-tirzepatida","tag-triumph","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-22 15:54:09","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560873"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560873\/revisions"}],"predecessor-version":[{"id":560875,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560873\/revisions\/560875"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560873"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}